MCKMcKesson Corporation

$896.78

$656.3452 weeks$994.59

Price

$896.78+28%1Y

1M+8.8%1Y+28%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Average

6/10

Value56

Quality62

Momentum48

Growth48

Strongest Quality, weakest Growth · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

McKesson Corporation together with its subsidiaries (collectively, the “Company,” “McKesson,” “we,” “our,” or “us” and other similar pronouns), which traces its business roots to 1833, is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable.

In the company’s own words · 10-K filed May 8, 2026 · SEC EDGAR

P/E (TTM)23.4

Market Cap$87.88B

1Y Return+28%

5Y Return+352%

Business segments

Q4 2025 · $105.82B

The company’s own SEC segment disclosure.

North American Pharmaceutical$88.32B83%
Oncology And Multispecialty$13.01B12%
Medical Surgical Solutions$2.99B3%
Prescription Technology Solutions$1.50B1%

McKesson Corporation (MCK) reported revenue of $96.3B in Q4 2026 (quarter ended March 31, 2026), up 6.0% from the same quarter a year earlier. That came with a gross margin of 4.2% and net income of $1.68B (1.7% of revenue). For the full year FY2026, revenue was $403.4B (+12% year on year) and net income $4.76B. Its largest segment in 2025-Q4 was North American Pharmaceutical at $88.3B, 83% of the disclosed total, just ahead of Oncology And Multispecialty at 12%.

Raw charts

11 series · TTM

As reported to the SEC, without any scoring.

Healthcare

Ranks #240 of 345 by Smart Score